Abstract | BACKGROUND: METHODS: Nonsquamous NSCLC patients with MPE following unsuccessful tube drainage or pleurodesis received bevacizumab (15 mg/kg) plus chemotherapy every three weeks. The primary endpoint was pleural effusion control rate (PECR), defined as the percentage of patients without reaccumulation of MPE at eight weeks. Secondary endpoints included pleural progression-free survival (PPFS), safety, and quality of life (QoL). RESULTS: CONCLUSIONS:
Bevacizumab plus chemotherapy is highly effective with acceptable toxicities in nonsquamous NSCLC patients with uncontrolled MPE, and should be considered as a standard therapy in this setting. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Bevacizumab plus chemotherapy is highly effective with acceptable toxicities in nonsquamous NSCLC patients with uncontrolled MPE. WHAT THIS STUDY ADDS:
Bevacizumab plus chemotherapy should be considered as a standard treatment option for patients with uncontrolled MPE. CLINICAL TRIAL REGISTRATION:
|
Authors | Rintaro Noro, Kunihiko Kobayashi, Jiro Usuki, Makiko Yomota, Masaru Nishitsuji, Tsuneo Shimokawa, Masahiro Ando, Mitsunori Hino, Koichi Hagiwara, Akihiko Miyanaga, Masahiro Seike, Kaoru Kubota, Akihiko Gemma, North East Japan Study group |
Journal | Thoracic cancer
(Thorac Cancer)
Vol. 11
Issue 7
Pg. 1876-1884
(07 2020)
ISSN: 1759-7714 [Electronic] Singapore |
PMID | 32421226
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. |
Chemical References |
- Pemetrexed
- Docetaxel
- Bevacizumab
- Carboplatin
- Erlotinib Hydrochloride
|
Topics |
- Adenocarcinoma of Lung
(drug therapy, etiology, pathology)
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bevacizumab
(administration & dosage)
- Carboplatin
(administration & dosage)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, etiology, pathology)
- Docetaxel
(administration & dosage)
- Erlotinib Hydrochloride
(administration & dosage)
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms
(drug therapy, etiology, pathology)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, etiology, pathology)
- Pemetrexed
(administration & dosage)
- Pleural Effusion, Malignant
(complications, drug therapy, pathology)
- Pleurodesis
(adverse effects)
- Prognosis
- Survival Rate
|